GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » 5-Year RORE %

Ulisse Biomed SpA (MIL:UBM) 5-Year RORE % : 0.00% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ulisse Biomed SpA 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Ulisse Biomed SpA's 5-Year RORE % for the quarter that ended in Jun. 2024 was 0.00%.

The industry rank for Ulisse Biomed SpA's 5-Year RORE % or its related term are showing as below:

MIL:UBM's 5-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -6.37
* Ranked among companies with meaningful 5-Year RORE % only.

Ulisse Biomed SpA 5-Year RORE % Historical Data

The historical data trend for Ulisse Biomed SpA's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ulisse Biomed SpA 5-Year RORE % Chart

Ulisse Biomed SpA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial - - - - -

Ulisse Biomed SpA Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ulisse Biomed SpA's 5-Year RORE %

For the Biotechnology subindustry, Ulisse Biomed SpA's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ulisse Biomed SpA's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ulisse Biomed SpA's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Ulisse Biomed SpA's 5-Year RORE % falls into.


';

Ulisse Biomed SpA 5-Year RORE % Calculation

Ulisse Biomed SpA's 5-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( -0.873-0 )
=/-0.873
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 5-year before.


Ulisse Biomed SpA  (MIL:UBM) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Ulisse Biomed SpA 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Ulisse Biomed SpA's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ulisse Biomed SpA Business Description

Traded in Other Exchanges
N/A
Address
Area Science Park - SS14 km.163, 5, Basovizza, ITA, 34149
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.

Ulisse Biomed SpA Headlines

No Headlines